18819-25-5

Basic information

• Product Name: 3-(trifluoromethyl)-5,6,7,8,9,10-hexahydro-11H-cyclohepta[b]quinolin-11-one
• CAS NO: 18819-25-5
• Molecular Formula: C₁₅H₁₄F₃NO
• Molecular Weight: 281.273
• Mol File: 18819-25-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 369.2°C at 760 mmHg
• Flash Point: 177.1°C
• Density: 1.32g/cm³
• Vapor Pressure: 1.2E-05mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: 3-(trifluoromethyl)-5,6,7,8,9,10-hexahydro-11H-cyclohepta[b]quinolin-11-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(trifluoromethyl)-5,6,7,8,9,10-hexahydro-11H-cyclohepta[b]quinolin-11-one(18819-25-5)
• EPA Substance Registry System: 3-(trifluoromethyl)-5,6,7,8,9,10-hexahydro-11H-cyclohepta[b]quinolin-11-one(18819-25-5)

Safety Data

• Hazardous Substances Data: 18819-25-5(Hazardous Substances Data)

Upstream product

• 4294-95-5 4-methoxyanthranilic acid 
• 502-42-1 cycloheptanone 

Relevant articles and documents

Optimization of 1,2,3,4-tetrahydroacridin-9(10 H)-ones as antimalarials utilizing structure-activity and structure-property relationships

Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC50 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.